Skip to main content

Atossa Genetics Inks NY, NJ-area Breast Cancer Dx Distribution Pact

NEW YORK (GenomeWeb News) – Atossa Genetics said today that it has signed up Millennium Healthcare to distribute its non-invasive breast cancer diagnostic test in the New York metro area and in northern New Jersey.

Under the agreement, Millennium Medical Devices will distribute and market Atossa's ForeCYTE Breast Health devices to managed-care networks, healthcare clinics, and physician practices.

Millennium has submitted an initial order for 10,000 of the ForeCYTE kits, which can detect early breast cancer and pre-cancerous conditions that could lead to cancer and which are present as much as eight years before mammography can detect a cancer, Seattle-based Atossa said.

The ForeCYTE test, which is administered in a doctor's office, detects and analyzes proteins found in samples of nipple aspirate fluid that are associated with pre-malignant or malignant cells.

The company said that the number of pre-malignant and malignant cells and the specific amount of proteins present also is used to calculate a lifetime breast cancer risk profile.

The samples are sent to Atossa's National Reference Library for Breast Cancer Health, which conducts the analysis, and the findings and risk profile are then returned to the physicians via a five-page report.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.